Literature DB >> 27009262

Effect of waivers of consent on recruitment in acute stroke trials: A systematic review.

William B Feldman1, Anthony S Kim2, S Andrew Josephson2, Daniel H Lowenstein2, Winston Chiong2.   

Abstract

There is urgent need for clinical trials of novel interventions to reduce the burden of acute ischemic stroke. A key impediment to such trials is slow recruitment. Since obtaining written informed consent in the setting of acute stroke is especially challenging, some experts have endorsed relaxing the requirement for informed consent by permitting verbal consent or waivers to facilitate recruitment. This systematic review of 36 randomized controlled trials of acute interventions for ischemic stroke assesses whether alternatives to written informed consent are associated with increased recruitment rates. After the exclusion of 2 outlier trials that differed from other trials in conduct and interventions studied, no association was observed on univariable analysis (8.9 participants/month in trials requiring written consent vs 6.1 participants/month in trials with alternatives, p = 0.43) or multivariable analysis (when adjusting for the number of centers, number of countries, and exclusions based on modified Rankin Scale scores). Alternatives to written informed consent in acute stroke trials may enable trial designs that would not be feasible otherwise. However, we did not find evidence that, within traditional trial designs, such alternatives are associated with faster recruitment.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Year:  2016        PMID: 27009262      PMCID: PMC4836887          DOI: 10.1212/WNL.0000000000002587

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  55 in total

1.  Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.

Authors:  Sanne M Zinkstok; Yvo B Roos
Journal:  Lancet       Date:  2012-06-28       Impact factor: 79.321

2.  Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial.

Authors:  Martin Ebinger; Benjamin Winter; Matthias Wendt; Joachim E Weber; Carolin Waldschmidt; Michal Rozanski; Alexander Kunz; Peter Koch; Philipp A Kellner; Daniel Gierhake; Kersten Villringer; Jochen B Fiebach; Ulrike Grittner; Andreas Hartmann; Bruno-Marcel Mackert; Matthias Endres; Heinrich J Audebert
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

3.  Stroke team remote evaluation using a digital observation camera in Arizona: the initial mayo clinic experience trial.

Authors:  Bart M Demaerschalk; Bentley J Bobrow; Rema Raman; Terri-Ellen J Kiernan; Maria I Aguilar; Timothy J Ingall; David W Dodick; Michael P Ward; Phillip C Richemont; Karina Brazdys; Tiffany C Koch; Madeline L Miley; Charlene R Hoffman Snyder; Doren A Corday; Brett C Meyer
Journal:  Stroke       Date:  2010-04-29       Impact factor: 7.914

4.  A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.

Authors:  Mark Parsons; Neil Spratt; Andrew Bivard; Bruce Campbell; Kong Chung; Ferdinand Miteff; Bill O'Brien; Christopher Bladin; Patrick McElduff; Chris Allen; Grant Bateman; Geoffrey Donnan; Stephen Davis; Christopher Levi
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

5.  Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study.

Authors:  Kazumi Kimura; Juya Aoki; Yuki Sakamoto; Kazuto Kobayashi; Kenichi Sakai; Takeshi Inoue; Yasuyuki Iguchi; Kensaku Shibazaki
Journal:  J Neurol Sci       Date:  2011-10-02       Impact factor: 3.181

6.  AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke.

Authors:  Wolf R Schäbitz; Rico Laage; Gerhard Vogt; Winfried Koch; Rainer Kollmar; Stefan Schwab; Dietmar Schneider; Gerhard F Hamann; Michael Rosenkranz; Roland Veltkamp; Jochen B Fiebach; Werner Hacke; James C Grotta; Marc Fisher; Armin Schneider
Journal:  Stroke       Date:  2010-10-14       Impact factor: 7.914

7.  Endovascular treatment for acute ischemic stroke.

Authors:  Alfonso Ciccone; Luca Valvassori; Michele Nichelatti; Annalisa Sgoifo; Michela Ponzio; Roberto Sterzi; Edoardo Boccardi
Journal:  N Engl J Med       Date:  2013-02-06       Impact factor: 91.245

8.  Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.

Authors:  G Torgano; B Zecca; V Monzani; A Maestroni; P Rossi; M Cazzaniga; D Manganaro; C Boiti; E Zilioli; G Borutti; F Falaschi; C Mandelli
Journal:  Cerebrovasc Dis       Date:  2010-01-15       Impact factor: 2.762

9.  A trial of imaging selection and endovascular treatment for ischemic stroke.

Authors:  Chelsea S Kidwell; Reza Jahan; Jeffrey Gornbein; Jeffry R Alger; Val Nenov; Zahra Ajani; Lei Feng; Brett C Meyer; Scott Olson; Lee H Schwamm; Albert J Yoo; Randolph S Marshall; Philip M Meyers; Dileep R Yavagal; Max Wintermark; Judy Guzy; Sidney Starkman; Jeffrey L Saver
Journal:  N Engl J Med       Date:  2013-02-08       Impact factor: 91.245

10.  Who will participate in acute stroke trials?

Authors:  S E Kasner; A Del Giudice; S Rosenberg; M Sheen; J M Luciano; B L Cucchiara; S R Messé; L H Sansing; J M Baren
Journal:  Neurology       Date:  2009-05-12       Impact factor: 9.910

View more
  2 in total

Review 1.  Trends in Recruitment Rates for Acute Stroke Trials, 1990-2014.

Authors:  William B Feldman; Anthony S Kim; Winston Chiong
Journal:  Stroke       Date:  2017-01-19       Impact factor: 7.914

2.  Deferred Consent in an Acute Stroke Trial from a Patient, Proxy, and Physician Perspective: A Cross-Sectional Survey.

Authors:  Inez Koopman; Dagmar Verbaan; W Peter Vandertop; Rieke van der Graaf; Erwin J O Kompanje; René Post; Bert A Coert; Martine C Ploem; Wouter M Sluis; Féline E V Scheijmans; Gabriel J E Rinkel; Mervyn D I Vergouwen
Journal:  Neurocrit Care       Date:  2021-10-05       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.